Evidence map›Paper›PMID 34515037›Full record

ArticleAmerican journal of nephrology2021

Preimplantation Genetic Testing for Kidney Disease-Related Genes: A Laboratory's Experience.

Jessica L Chaperon, Nina M Wemmer, Trudy A McKanna, Dinah M Clark, Maggie A Westemeyer, Philippe Gauthier, Yan Bai, Jessica M Coleman

Open access · hybridAbstract read
In one paragraph

Article in American journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jessica L ChaperonNatera, Inc., San Carlos, California, USA.
Nina M WemmerNatera, Inc., San Carlos, California, USA.
Trudy A McKannaNatera, Inc., San Carlos, California, USA.
Dinah M ClarkNatera, Inc., San Carlos, California, USA.
Maggie A WestemeyerNatera, Inc., San Carlos, California, USA.
Philippe GauthierNatera, Inc., San Carlos, California, USA.
Yan BaiNatera, Inc., San Carlos, California, USA.
Jessica M ColemanNephrology and Hypertension Medical Associates, P.C., Beaufort, South Carolina, USA.
Natera (United States) · USUniversity of South Carolina Beaufort · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent literature highlights the clinical utility of genetic testing for patients with kidney disease. Genetic testing provides significant benefits for reproductive risk counseling, including the option of in vitro fertilization with preimplantation genetic testing for monogenic disease (PGT-M). PGT-M allows for a significant reduction in risk for a pregnancy affected with the familial disease. We aim to summarize our experience with PGT-M for genes with kidney involvement as either a primary or secondary feature of the disease.

methodsAll PGT-M tests performed by the reference laboratory between September 2010 and July 2020 were reviewed for clinical indication and cases for which the disease tested included a renal component. Each patient referred for PGT-M had an existing molecular genetic diagnosis themselves or in their family. Frequency of each condition, gene, inheritance pattern, and year over year increase in referral cases was analyzed.

resultsIn the study cohort, the most common disease targeted was autosomal dominant polycystic kidney disease, caused by pathogenic variants in the PKD1 or PKD2 genes, which accounted for 16.5% (64/389) of cases. The 5 most common referral indications accounted for 51.9% (202/389) of the cases. Autosomal recessive inheritance accounted for 52.0% (26/50) of conditions for which PGT-M was performed. The number of PGT-M tests performed for conditions that included either primary or secondary kidney disease increased from 5 cases in 2010 to 47 cases in the 2020 study period. DISCUSSION/

conclusionThese data suggest that the pursuit of PGT-M by couples at risk for passing on conditions with a kidney component is common and has significantly increased since 2010. With this rising trend of patients undergoing PGT-M and the prerequisite of molecular genetic confirmation in the PGT-M process, this study underscores the importance of the reproductive component to a molecular genetic diagnosis for patients with kidney disease, especially as the accessibility of genetic testing and utilization by nephrologists grows.

Indexed as

Genetic TestingAdultFemaleHumansKidney DiseasesLaboratories, ClinicalMiddle AgedPregnancyPreimplantation DiagnosisRetrospective StudiesYoung AdultChronic kidney diseaseMonogenic kidney diseasePreimplantation genetic testing

Identifiers

PMID34515037
PMCPMC8619921
OpenAlexW3197516169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.